Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-54389
ACS Chem Neurosci 2017 May 16;88:1681-1687. doi: 10.1021/acschemneuro.7b00117.
Show Gene links Show Anatomy links

Subtype-Specific Agonists for NMDA Receptor Glycine Binding Sites.

Maolanon AR, Risgaard R, Wang SY, Snoep Y, Papangelis A, Yi F, Holley D, Barslund AF, Svenstrup N, Hansen KB, Clausen RP.


???displayArticle.abstract???
A series of analogues based on serine as lead structure were designed, and their agonist activities were evaluated at recombinant NMDA receptor subtypes (GluN1/2A-D) using two-electrode voltage-clamp (TEVC) electrophysiology. Pronounced variation in subunit-selectivity, potency, and agonist efficacy was observed in a manner that was dependent on the GluN2 subunit in the NMDA receptor. In particular, compounds 15a and 16a are potent GluN2C-specific superagonists at the GluN1 subunit with agonist efficacies of 398% and 308% compared to glycine. This study demonstrates that subunit-selectivity among glycine site NMDA receptor agonists can be achieved and suggests that glycine-site agonists can be developed as pharmacological tool compounds to study GluN2C-specific effects in NMDA receptor-mediated neurotransmission.

???displayArticle.pubmedLink??? 28514141
???displayArticle.pmcLink??? PMC5559341
???displayArticle.link??? ACS Chem Neurosci
???displayArticle.grants??? [+]


References [+] :
Bräuner-Osborne, Ligands for glutamate receptors: design and therapeutic prospects. 2000, Pubmed